Biologics In Focus

Welcome to the November edition of "Biologics In Focus", our monthly newsletter that brings you the latest highlights from the biologics industry.

This month, we’re excited to share key insights, including advancements in biopharma manufacturing, the completion of our $1.2 billion acquisition to expand large-scale biologics production, and our partnerships with Pheast Therapeutics and Kivu Biosciences to advance cancer therapeutics. We’ll also bring you the latest updates from Lonza, along with a real-world customer story that showcases the innovation and collaboration driving our community forward.

Join over 103K subscribers who stay informed with our monthly updates - subscribe today and share the newsletter with your network.

Lonza News and Updates

Lonza Concludes $1.2 Billion Acquisition of Roche’s U.S. Biologics Facility

We are excited to announce the completion of the $1.2 billion acquisition of Roche’s biologics facility in Vacaville, California. This deal expands our manufacturing capabilities in the U.S., enhancing the capacity to produce large-scale biologics. This facility, featuring significant bioreactor capacity, will support our strategy to meet the growing demand for commercial biologics. Additionally, we plan to invest in upgrading the site and integrating it into our global network for advanced biomanufacturing.

Insights and Analysis

Experts in Expression: Recent Advances in CHO Upstream Bioproduction

Discover in our consolidated e-book "Experts in Expression Technology" the latest advancements in expression technologies for biologics. It provides insights from industry experts on optimizing protein expression systems, covering innovative methods, industry challenges, and our approaches to streamline biologics production. This resource aims to support biopharma professionals in improving expression yields and efficiency for therapeutic development.

Tech Transfer Strategies and Best Practices to Optimize Your Clinical and Commercial Supply

This on-demand webinar focuses on strategies and best practices for effective technology transfer in biologics, aimed at optimizing both clinical and commercial supply chains. It addresses essential methodologies to ensure smooth and efficient transfers, while minimizing risks and maximizing production consistency. Geared towards biopharma professionals, the session provides actionable insights on streamlining operations and adhering to regulatory standards throughout the technology transfer process.

Exploring Technologies for cGMP Success with Encapsulation of Nucleic Acid-based Therapeutics

This white paper is essential reading for professionals aiming to advance therapeutic development with mRNA and nucleic acid-based therapeutics. Gain valuable insights into encapsulation technologies designed to overcome the unique challenges of delivering these cutting-edge therapies efficiently. Discover methods to ensure stability and effectiveness and learn how to navigate the complexities of therapeutic delivery.

Interview with Dr. Manuela Schneider-H?fferer, Head of Commercial Development and Strategic Marketing at Lonza

In this interview, Manuela Schneider-Hoferer, Ph.D., Head of Commercial Development and Strategic Marketing, discusses trends and advancements in biopharma manufacturing. She shares insights into Lonza’s role in the evolving biologics market, focusing on innovation, sustainability, and scalability in therapeutic production, and highlights our approach to global healthcare challenges through advanced biomanufacturing solutions.

Lonza in the Press

Pheast Partners with Lonza to Produce Cancer-Gobbling CD24 Drug

Read about the partnership with Pheast Therapeutics to develop and produce a novel CD24-based therapeutic for cancer treatment. The "cancer-gobbling" drug leverages CD24 technology to enhance the immune system's ability to target and eliminate cancer cells. Lonza will provide manufacturing support to advance this innovative approach, potentially offering new options in cancer immunotherapy.

Integrated Expertise: Optimize Cell Culture Media Challenges

Combining expertise in drug production enhances efficiency, fosters innovation, and improves biologics and cell and gene therapy. This article explores how integrating specialized knowledge in pharmaceutical manufacturing addresses complex problems, accelerates development, and ensures high-quality outcomes.

With $92M, Kivu Sets Out to Make ‘Kinder, Gentler’ ADCs

Kivu Biosciences has secured $92 million in Series A funding, emphasizing its partnership with Synaffix to create safer antibody-drug conjugates (ADCs) for cancer treatment. Using our advanced linker technology, Kivu aims to improve ADC stability and minimize side effects in targeting solid tumors. This collaboration leverages Synaffix’s innovations to address the traditional toxicity issues in ADC therapies, promising more precise and patient-friendly options for cancer care.

Customer Case Study

Tailoring Analytical Method Development to Minimize the Risk of Post Translational Modification

Our expert, Maurizio Muroni, Ph.D., shares how our advanced analytical method development helped customers streamline their biologics manufacturing process. By leveraging automation, high-throughput screening, and data-driven techniques, the customer improved product quality and accelerated timelines. Explore how innovative solutions can revolutionize analytics, driving efficiency and success in biopharmaceutical development.

Key Upcoming Events

View more events.

Upcoming Webinars

Monday, 2 December 2024. 11am ET | 5pm CET

Early Preclinical Development of mRNA/LNP projects - Setting Up Your Project for a Successful Transition to cGMP Manufacturing

Tuesday, 3 December 2024. 11am ET | 5pm CET

Charting a Successful CMC Journey for your ADC Drug Product

Thank you for reading. Remember to subscribe so you never miss our monthly updates.

If you'd like to find out more about Lonza Biologics, you can visit our website or contact one of our team of experts.